Hormonal Therapy and Risk of Breast Cancer in Mexican Women

The use of hormonal therapies, including hormonal contraceptives (HC) and postmenopausal hormone replacement therapy (HRT) have been shown to influence breast cancer (BC) risk. However, the variations of these effects among populations and ethnic groups are not completely documented, especially among Hispanic women. We evaluated the association between HC and premenopausal BC risk, and between HRT and postmenopausal BC risk in Mexican women. Data from a Mexican multi-center population-based case–control study ofwomen aged 35 to 69 years were analysed. A total of 1000 cases and 1074 matched controls were recruited between 2004 and 2007. Information on hormonal therapy was collected through a structured questionnaire. Results were analysed using conditional logistic regression models. Overall, HC were used by 422/891 (47.3%) premenopausal women and HRT was used by 220/1117 (19.7%) postmenopausal women. For HC, odds ratios (ORs) for BC were 1.11 (95% confidence interval (CI): 0.82, 1.49) for current users and 1.68 (95% CI: 0.67, 4.21) for ever-users. No clear effect of duration of use was observed. For HRT, the OR for BC was significantly increased in ever users (OR: 1.45; 95% CI: 1.01, 2.08). A non-significant increased risk was observed for combined estrogen/progestin, (OR =  1.85; 95% CI: 0.84, 4.07) whereas no effect was observed for the use of estrogen alone (OR = 1.14; 95% CI: 0.68, 1.91). Our results indicate that, HC had a non-significant effect on the risk of pre-menopausal BC, but suggested that injected contraceptives may slightly increase the risk, whereas HRT had a significant effect on post-menopausal BC in this population. This study provides new information about the effects of HC and HRT on BC risk in a Mexican population, which may be of relevance for the population of Latin America as a whole.

[1]  Isabelle Romieu,et al.  Role of Obesity in the Risk of Breast Cancer: Lessons from Anthropometry , 2013, Journal of oncology.

[2]  F. Knaul,et al.  Breast cancer in Mexico: a growing challenge to health and the health system. , 2012, The Lancet. Oncology.

[3]  E. Lund,et al.  The risk of breast cancer linked to menopausal hormone therapy. , 2012, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[4]  Rongwei Fu,et al.  Risk Factors for Breast Cancer for Women Aged 40 to 49 Years , 2012, Annals of Internal Medicine.

[5]  V. Beral,et al.  Injectable and Oral Contraceptive Use and Cancers of the Breast, Cervix, Ovary, and Endometrium in Black South African Women: Case–Control Study , 2012, PLoS medicine.

[6]  S. Vernon,et al.  A review of body size and breast cancer risk in Hispanic and African American women , 2011, Cancer.

[7]  E. Petru,et al.  Hormonelle Kontrazeption und Brustkrebsrisiko , 2010, Wiener Medizinische Wochenschrift.

[8]  J. Manson,et al.  Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. , 2010, JAMA.

[9]  B. Bonanni,et al.  Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. , 2010, European journal of cancer.

[10]  E. Ziv,et al.  European Ancestry Is Positively Associated with Breast Cancer Risk in Mexican Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[11]  I. Romieu,et al.  Alcohol and risk of breast cancer in Mexican women , 2010, Cancer Causes & Control.

[12]  T. Manninen,et al.  Progestins regulate genes that can elicit both proliferative and antiproliferative effects in breast cancer cells. , 2008, Oncology reports.

[13]  T. Byers,et al.  Oral, injected and implanted contraceptives and breast cancer risk among U.S. Hispanic and non‐Hispanic white women , 2007, International journal of cancer.

[14]  V. Beral,et al.  Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis. , 2006, The Lancet. Oncology.

[15]  Francesmary Modugno,et al.  Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. , 2006, Mayo Clinic proceedings.

[16]  Garnet L Anderson,et al.  Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. , 2006, JAMA.

[17]  M. Pike,et al.  Postmenopausal hormone therapy and breast cancer risk: The multiethnic cohort , 2006, International journal of cancer.

[18]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[19]  A. Paterson,et al.  Mammographic breast density as an intermediate phenotype for breast cancer. , 2005, The Lancet. Oncology.

[20]  K. Straif,et al.  Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. , 2005, The Lancet. Oncology.

[21]  V. Beral,et al.  Current evidence about the effect of hormone replacement therapy on the incidence of major conditions in postmenopausal women , 2005, BJOG : an international journal of obstetrics and gynaecology.

[22]  M. Pike,et al.  An overview of menopausal oestrogen–progestin hormone therapy and breast cancer risk , 2005, British Journal of Cancer.

[23]  F. Clavel-Chapelon,et al.  Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort , 2005, International journal of cancer.

[24]  A. Eggen,et al.  Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer study , 2004, International journal of cancer.

[25]  A. Tjønneland,et al.  Hormone replacement therapy in relation to breast carcinoma incidence rate ratios , 2004, Cancer.

[26]  N. Keiding,et al.  Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe , 2004, International journal of cancer.

[27]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[28]  Mark Garton,et al.  Breast cancer and hormone-replacement therapy: the Million Women Study , 2003, The Lancet.

[29]  C. Agardh,et al.  A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden) , 2003, Cancer Causes & Control.

[30]  P. Porter,et al.  Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. , 2003, JAMA.

[31]  J. Samet,et al.  Hormone replacement therapy and breast carcinoma risk in Hispanic and non‐Hispanic women , 2002, Cancer.

[32]  M. Pike,et al.  Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[33]  M. Pike,et al.  Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[34]  J. Samet,et al.  Reproductive risk factors for breast cancer in Hispanic and non-Hispanic white women: the New Mexico Women's Health Study. , 1998, American journal of epidemiology.

[35]  V. Beral,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[36]  Julian Peto,et al.  Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies , 1996, The Lancet.

[37]  R. Bulbrook.  Hormones and breast cancer. , 1992, Oxford reviews of reproductive biology.

[38]  S. Zervoudis,et al.  The role of oral contraception use in the occurrence of breast cancer. A retrospective study of 405 patients. , 2011, Clinical and experimental obstetrics & gynecology.

[39]  Iarc Monographs,et al.  Combined estrogen-progestogen contraceptives and combined estrogen-progestogen menopausal therapy. , 2007, IARC monographs on the evaluation of carcinogenic risks to humans.

[40]  L. Bernstein,et al.  Ethnicity‐related variation in breast cancer risk factors , 2003, Cancer.

[41]  P. Newcomb,et al.  Hormone replacement therapy in relation to breast cancer. , 2002, JAMA.

[42]  M. Bronfman,et al.  [Strategies for improving the therapeutic patterns used in acute diarrhea in primary medical care units. II. The measurement of inequality: a methodologic strategy, analysis of the socioeconomic features of the sample]. , 1988, Archivos de investigacion medica.